Xiao Yuhong, Isaacs Stuart N
Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Penn Institute for RNA Innovation, University of Pennsylvania, Philadelphia, PA, USA.
Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Penn Institute for RNA Innovation, University of Pennsylvania, Philadelphia, PA, USA; Infectious Diseases Section, Department of Medicine, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.
Trends Pharmacol Sci. 2024 Dec;45(12):1086-1088. doi: 10.1016/j.tips.2024.10.015. Epub 2024 Nov 12.
The unprecedented global spread of monkeypox (mpox) has reinvigorated the pursuit of next-generation poxvirus vaccines. Given the success of the mRNA-lipid nanoparticle (LNP) vaccine platform to vaccinate against SARS-CoV-2, candidate poxvirus mRNA vaccines, as recently reported by Zuiani et al. and Mucker et al., demonstrate success in nonhuman primate (NHP) models and provide insights into the basis of the protective immune response.
猴痘（mpox）在全球前所未有的传播态势，重新激发了人们对下一代痘病毒疫苗的研发热情。鉴于信使核糖核酸-脂质纳米颗粒（mRNA-LNP）疫苗平台在预防严重急性呼吸综合征冠状病毒2（SARS-CoV-2）方面取得的成功，如祖亚尼等人和穆克等人最近报道的那样，候选痘病毒信使核糖核酸疫苗在非人类灵长类动物（NHP）模型中取得了成功，并为保护性免疫反应的基础提供了见解。
